Nyrada
Menu
NYR:
Market Cap*:
Price Delay ~20min
Home
About Us
Company Overview
Board of Directors
Management
Scientific Advisory Board
Corporate Governance
Our Science
Lead Drug Development
Brain Injury Program
Cholesterol Lowering Program
Technical Glossary
Drug Development Pathway
Investors
Investor Welcome
ASX Announcements
Brain Injury Program
Cholesterol-Lowering Program
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Key Dates
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Extraordinary General Meeting
Past Shareholder Meetings
News & Insights
Presentations & Interviews
Media
Newsletters
Publications
Contact Us
Contact Us
Working at Nyrada
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
>
Cholesterol-Lowering Program
Investor Welcome
ASX Announcements
Brain Injury Program
Cholesterol-Lowering Program
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Key Dates
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Extraordinary General Meeting
Past Shareholder Meetings
Cholesterol-Lowering Program
Filter by Year:
2023
2022
2021
2020
22-Dec-2021
Cholesterol-Lowering Program Pathway to Phase I
13-Aug-2021
NYX-PCSK9i In Vivo Study Exploratory Analysis Results
30-Jul-2021
Nyrada Announces US Patent Grant for PCSK9 Inhibitor
29-Jun-2021
NYX-PCSK9i with Statin Achieves 65% Cholesterol Reduction
5-May-2021
NYR Announces New Potent Cholesterol-Lowering Candidates
25-Jan-2021
Nyrada Reports Further Results from Cholesterol Study
1